CJC-1295 + Ipamorelin Blend

Two receptors drive pituitary GH release: the GHRH receptor (activated by GHRH and its analogs) and the ghrelin receptor GHS-R1a (activated by ghrelin, ipamorelin, and the GHRP family). They work through separate intracellular pathways — cAMP for GHRH-R, calcium and PKC for GHS-R — and when both are activated simultaneously, GH output is larger than either pathway produces alone. This blend is that combination pre-mixed: CJC-1295 without DAC (Mod GRF 1-29) as the GHRH component, ipamorelin as the selective GHSR agonist. One vial, one reconstitution, co-administered.

Why the Combination Specifically

The selectivity of ipamorelin is what makes this pairing clean. GHRP-2 and GHRP-6 also activate GHS-R but raise cortisol and prolactin as side effects. Ipamorelin activates GHS-R with minimal effect on those axes. For research where the question is specifically about GH axis dynamics — without cortisol or prolactin elevation as confounding variables — ipamorelin is the right GHSR agonist for this combination.

The combination also preserves somatostatin sensitivity, meaning the feedback architecture of the GH axis stays intact. Pulses are larger, but the somatostatin brake still functions. This is different from exogenous GH administration, which bypasses pituitary regulation entirely. For GH secretagogue synergy, pulse amplitude and frequency analysis, or age-related somatopause research, the dual-receptor stimulation is the experimental foundation.

Specifications

Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.

Quality: Every product ships to a ≥98% supplier batch specification; selected lots are independently tested by Janoshik Analytical (HPLC + mass spectrometry; 99.4% average purity across published reports), searchable by batch code at certapeptides.com/verify. EU-based QC under CERTALAB S.R.L.

For research purposes only. Not for human consumption.